HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice.

Eur J Clin Chem Clin Biochem

Rambam Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Published: October 1995

Epidemiological evidence suggests that plasma high-density lipoprotein (HDL) is protective against coronary artery disease, whereas oxidatively modified low density lipoprotein is atherogenic. Human apolipoprotein A-I transgenic mice with overexpression of the human apolipoprotein A-I gene have increased plasma levels of apolipoprotein A-I and HDL-cholesterol. We analyzed LDL oxidation by determination of LDL associated malondialdehyde, peroxides and conjugated dienes. The present study demonstrates that HDL from both normal and human apolipoprotein A-I transgenic mice at similar concentrations inhibits LDL (protein concentration 500 mg/l) lipid peroxidation, but the effect of the human apolipoprotein A-I transgenic mice HDL was two-fold greater than that of HDL derived from normal mice. In addition, the electrophoretic mobility of oxidatively modified LDL was reduced about two-fold in the presence of human apolipoprotein A-I transgenic mice HDL than that obtained in the presence of normal mice HDL. We thus suggest that human apolipoprotein A-I possesses antioxidant properties which might neutralize LDL lipid peroxidation. This may underline the mechanism responsible for the lower prevalence of atherosclerosis in subjects with high plasma levels of HDL and apolipoprotein A-I.

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm.1995.33.10.721DOI Listing

Publication Analysis

Top Keywords

apolipoprotein a-i
36
human apolipoprotein
24
transgenic mice
20
a-i transgenic
16
mice hdl
12
a-i
9
hdl
8
hdl apolipoprotein
8
low density
8
density lipoprotein
8

Similar Publications

: Familial hypercholesterolemia (FH) is a monogenic dyslipidemia that leads to early cardiovascular events. Subclinical atherosclerosis refers to the formation of atheromatous plaques in arterial beds before any clinical events. In our study, we investigated the presence, extent, and independent predictors of subclinical atherosclerosis among patients diagnosed with FH.

View Article and Find Full Text PDF

Objective: Recent studies suggested that the medical control of atherogenic lipoproteins is not sufficient for stroke prevention. A low apolipoprotein A-I (apoA-I) level may play a crucial role in the anti-atherogenic effects of high-density lipoprotein (HDL-C) and may also be associated with symptomatic vulnerable plaques in carotid artery stenosis. Therefore, the present study investigated the relationship between apoA-I levels and the status of carotid artery stenosis.

View Article and Find Full Text PDF

Objective: This study aims to evaluate the relationship between apolipoproteins (ApoA1, ApoB, and the ApoB/A1 ratio) and the incidence of major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) and impaired kidney function, assessing their potential role in secondary prevention.

Method: A prospective cohort of 1,640 patients with impaired kidney function who underwent percutaneous coronary intervention in China was analyzed. Patients were categorized based on the measurements of ApoA1, ApoB, and ApoB/A1 ratio.

View Article and Find Full Text PDF

Background: In preliminary research and literature review, we identified a potential link between chronic obstructive pulmonary disease (COPD) and lipid metabolism. Therefore, this study employed Mendelian randomization (MR) analysis to investigate the potential causal connection between blood lipids and COPD.

Materials And Methods: A genome-wide association study (GWAS) on COPD was conducted, encompassing a total of 112,583 European participants from the MRC-IEU.

View Article and Find Full Text PDF

High apolipoprotein B-containing (apoB-containing) low-density lipoproteins (LDLs) and low apoA1-containing high-density lipoproteins (HDLs) are associated with atherosclerotic cardiovascular diseases. In search of a molecular regulator that could simultaneously and reciprocally control both LDL and HDL levels, we screened a microRNA (miR) library using human hepatoma Huh-7 cells. We identified miR-541-3p that both significantly decreases apoB and increases apoA1 expression by inducing mRNA degradation of 2 different transcription factors, Znf101 and Casz1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!